These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31914201)

  • 1. Novel Combination Shows Strong Antitumor Activity in Metastatic Renal Cell Carcinoma.
    Kahl KL
    Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914201
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy in kidney cancer: the next revolution?
    Buti S; Bersanelli M
    Lancet Oncol; 2015 Nov; 16(15):1441-1442. PubMed ID: 26482275
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenvatinib shows promise.
    Stone L
    Nat Rev Urol; 2015 Dec; 12(12):654. PubMed ID: 26526757
    [No Abstract]   [Full Text] [Related]  

  • 4. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Ren M; Dutcus C; Larkin J
    Lancet Oncol; 2016 Jan; 17(1):e4-5. PubMed ID: 26758760
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy in patients with metastatic renal cell carcinoma.
    Escudier BJ
    Clin Adv Hematol Oncol; 2010 Oct; 8(10):665-6. PubMed ID: 21317861
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
    Glen H
    Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma].
    Saillant A; Borchiellini D
    Bull Cancer; 2022; 109(7-8):737-738. PubMed ID: 35599170
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approves Drug Combo for Kidney Cancer.
    Cancer Discov; 2016 Jul; 6(7):687-8. PubMed ID: 27267515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metastasized renal cell carcinoma - research subjects needed!].
    Aktuelle Urol; 2014 Mar; 45(2):99. PubMed ID: 24700063
    [No Abstract]   [Full Text] [Related]  

  • 11. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B
    J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract]   [Full Text] [Related]  

  • 12. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
    Mehta A; Sonpavde G; Escudier B
    Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
    Iacovelli R; Alesini D; Palazzo A; Trenta P; Santoni M; De Marchis L; Cascinu S; Naso G; Cortesi E
    Cancer Treat Rev; 2014 Mar; 40(2):271-5. PubMed ID: 24070900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC.
    Romero D
    Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37507496
    [No Abstract]   [Full Text] [Related]  

  • 16. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
    Haberkorn BC; Eskens FA
    Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
    Jacob A; Shook J; Hutson T
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393
    [No Abstract]   [Full Text] [Related]  

  • 20. Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy.
    Sun M; Bianchi M; Hansen J; Trinh QD; Karakiewicz PI
    J Clin Oncol; 2012 Nov; 30(31):3901; author reply 3902. PubMed ID: 22987077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.